ZA91620B - Cyclodextrin based erythropoientin formulation - Google Patents

Cyclodextrin based erythropoientin formulation

Info

Publication number
ZA91620B
ZA91620B ZA91620A ZA91620A ZA91620B ZA 91620 B ZA91620 B ZA 91620B ZA 91620 A ZA91620 A ZA 91620A ZA 91620 A ZA91620 A ZA 91620A ZA 91620 B ZA91620 B ZA 91620B
Authority
ZA
South Africa
Prior art keywords
erythropoietin
erythropoientin
formulation
gamma
beta
Prior art date
Application number
ZA91620A
Other languages
English (en)
Inventor
Frank Jozef Konings
Jozef Konings Frank
Marcus Joannes Maria Noppe
Joannes Maria Noppe Marcus
Jean Louis Mesens
Louis Mesens Jean
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA91620(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA91620B publication Critical patent/ZA91620B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA91620A 1990-01-29 1991-01-28 Cyclodextrin based erythropoientin formulation ZA91620B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation

Publications (1)

Publication Number Publication Date
ZA91620B true ZA91620B (en) 1992-10-28

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA91620A ZA91620B (en) 1990-01-29 1991-01-28 Cyclodextrin based erythropoientin formulation

Country Status (20)

Country Link
US (1) US5376632A (fr)
EP (1) EP0513072B1 (fr)
JP (1) JP2997052B2 (fr)
KR (1) KR0183445B1 (fr)
AT (1) ATE107518T1 (fr)
AU (1) AU648061B2 (fr)
CA (1) CA2074820C (fr)
DE (1) DE69102627T2 (fr)
DK (1) DK0513072T3 (fr)
ES (1) ES2059115T3 (fr)
FI (1) FI105012B (fr)
GB (1) GB9001987D0 (fr)
HU (1) HU218213B (fr)
IE (1) IE65209B1 (fr)
IL (1) IL97019A (fr)
NO (1) NO304728B1 (fr)
NZ (1) NZ236938A (fr)
PT (1) PT96593B (fr)
WO (1) WO1991011200A1 (fr)
ZA (1) ZA91620B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
NZ337465A (en) * 1997-03-18 2002-04-26 Roche Diagnostics Gmbh Pharmaceutical containing erythropoietin and iron preparations for treating haemodialysis patients or anaemias
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
CA2342797A1 (fr) 1998-09-02 2000-03-09 Allergan Sales, Inc. Compositions contenant de la cyclodextrine et un agent conservateur
EP1181036B1 (fr) * 1999-04-09 2008-07-23 Ortho-Mcneil Pharmaceutical, Inc. Composition pharmaceutique d'erythropoietine
EP1336410A4 (fr) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd Preparations proteiniques a injecter
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
EP1413310A1 (fr) * 2001-07-09 2004-04-28 Yamanouchi Pharmaceutical Co. Ltd. Compositions a liberation prolongee a injecter et procede de production associe
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004108152A1 (fr) * 2003-06-10 2004-12-16 Lg Life Sciences Ltd. Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique
EP1537876A1 (fr) * 2003-12-01 2005-06-08 BioGeneriX AG Formulation d'une solution d'érythropoiétine
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
AU2007325576B2 (en) 2006-10-20 2013-01-10 Icos Corporation Compositions of Chk1 inhibitors
ES2632164T3 (es) * 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
KR0183445B1 (en) 1999-05-01
NZ236938A (en) 1992-07-28
AU7149791A (en) 1991-08-21
EP0513072A1 (fr) 1992-11-19
NO922990D0 (no) 1992-07-29
ES2059115T3 (es) 1994-11-01
GB9001987D0 (en) 1990-03-28
DE69102627T2 (de) 1994-11-03
IE910286A1 (en) 1991-07-31
DK0513072T3 (da) 1994-08-01
PT96593A (pt) 1991-10-15
IE65209B1 (en) 1995-10-04
IL97019A0 (en) 1992-03-29
WO1991011200A1 (fr) 1991-08-08
HU218213B (hu) 2000-06-28
CA2074820A1 (fr) 1991-07-30
IL97019A (en) 1997-07-13
EP0513072B1 (fr) 1994-06-22
FI923402A (fi) 1992-07-28
FI105012B (fi) 2000-05-31
HUT62198A (en) 1993-04-28
NO922990L (no) 1992-07-29
NO304728B1 (no) 1999-02-08
AU648061B2 (en) 1994-04-14
FI923402A0 (fi) 1992-07-28
DE69102627D1 (de) 1994-07-28
ATE107518T1 (de) 1994-07-15
JPH05503700A (ja) 1993-06-17
JP2997052B2 (ja) 2000-01-11
PT96593B (pt) 2001-06-29
HU9202432D0 (en) 1992-10-28
US5376632A (en) 1994-12-27
CA2074820C (fr) 2003-10-14

Similar Documents

Publication Publication Date Title
KR0183445B1 (en) Improved cyclodextrin based erythropoietin formulation
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
CA2091360A1 (fr) Fuorate de mometasone monohydrate, son procede de fabrication et ses compositions pharmaceutiques
HU200943B (en) Process for producing pharmaceutical compositions comprising active ingredients which are instable or badly soluble in water
AU3229789A (en) Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation
IT9019829A0 (it) Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
ATE132518T1 (de) Hilfstoffzusammensetzungen in fester form dispergierbar in wasserigen medien und verfahren zur herstellung davon
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
EP0422497A3 (en) Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them
HU9203649D0 (en) Method for producing inclusion compounds of nimesulide with cyclodextrines and pharmaceutical preparatives containing these compounds
NO922682L (no) Polysakkaridblanding, fremgangsmaate for dens fremstillingog anvendelse derav
ATE291058T1 (de) Vernetzerfreie zubereitungen
MD679F1 (en) Inclusion complex of N-ethoxycarbonyl-3-morpholinsydnonimine or salts thereof with cyclodextrin or its derivatives, preparation thereof and pharmaceutical compositions containing them, method of preparation thereof and treatment method
IT1264495B1 (it) Complessi solubili in acqua di glicosaminoglicani, loro procedimento di preparazione e composizioni farmaceutiche che li contengono